Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
4 hedge funds and large institutions have $23K invested in Northwest Biotherapeutics, Inc. Common stock in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
21% less capital invested
Capital invested by funds: $29K → $23K (-$6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WPP
Whalerock Point Partners
Providence,
Rhode Island
|
+$2K |
Top Sellers
NWBO Hedge Fund Activity: Q3 2018 in Review
4 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2018, worth a combined $23K — down 21% from $29K a quarter earlier.
Fund positioning in NWBO was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Whalerock Point Partners, adding an estimated $2K.
- 4 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $23K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2018, down 21% quarter-over-quarter.
- 0 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2018 and 0 closed out.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2018 was Whalerock Point Partners, an estimated $2K added.
Based on aggregated 13F filings for Q3 2018.